<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=28719"><dc:title>Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency</dc:title><dc:creator>Phillip,	Moshe	(Avtor)
	</dc:creator><dc:creator>Abuzzahab,	M. Jennifer	(Avtor)
	</dc:creator><dc:creator>Pietropoli,	Alberto	(Avtor)
	</dc:creator><dc:creator>Ferran,	Jean-Marc	(Avtor)
	</dc:creator><dc:creator>Højby Rasmussen,	Michael	(Avtor)
	</dc:creator><dc:creator>Kelepouris,	Nicky	(Avtor)
	</dc:creator><dc:creator>Kotnik,	Primož	(Avtor)
	</dc:creator><dc:creator>Polak,	Michel	(Avtor)
	</dc:creator><dc:creator>Sävendahl,	Lars	(Avtor)
	</dc:creator><dc:subject>comparative outcomes</dc:subject><dc:subject>growth hormon treatment</dc:subject><dc:subject>growth hormon deficiency</dc:subject><dc:subject>pediatrics</dc:subject><dc:description>Context: GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited. Objective: To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH). Methods: This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged &lt;18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-naïve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for ≤10 years. Results: The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was −1.21 (1.09) and −0.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals. Conclusion: GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile.</dc:description><dc:date>2025</dc:date><dc:date>2026-03-31 09:06:54</dc:date><dc:type>Neznano</dc:type><dc:identifier>28719</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
